Exploring the Role of Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

ON SEPTEMBER 11, 2022, OncLive® brought together medical oncologists who specialize in the treatment of non–small cell lung cancer (NSCLC). Moderated by Grace K. Dy, MD, the objectives of the workshop were to evaluate the potential role and impact of new antibody-drug conjugates (ADCs) in the treatment of patients with NSCLC.

Related Videos
View All
Related Content